Literature DB >> 19539567

Prostaglandin E2 signaling through E prostanoid receptor 2 impairs proliferative response of double negative regulatory T cells.

Boris P L Lee1, Stephen C Juvet, Li Zhang.   

Abstract

Limited data are available on the mechanisms that constrain the function of regulatory populations of T cells. Prostaglandin E2 (PGE2) is an endogenous membrane phospholipid metabolite that has important immunomodulatory effects on T cell function. Our previous microarray data indicated that E prostanoid receptor 2 (EP2), a receptor for PGE2, is expressed by regulatory alphabetaTCR(+) CD4(-) CD8(-) NK1.1(-) double negative T (DN Treg) cell clones but not by their non-regulatory natural mutants. Hence, the hypothesis that PGE2 may influence DN Treg cell proliferation and/or regulatory function was tested in this study. Our data indicate that PGE2 acts via the EP2 receptor on DN Treg cells to inhibit their proliferation, an effect reproduced by the EP2-specific agonist butaprost and abrogated by the EP2 antagonist AH6809. In contrast, PGE2 did not affect the ability of DN Treg cells to kill syngeneic CD8(+) T cells activated by allogeneic stimulation. Together, these findings suggest a role for PGE2 in limiting the expansion of DN Treg cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19539567     DOI: 10.1016/j.intimp.2009.01.023

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  11 in total

Review 1.  COX-2 and PGE2-dependent immunomodulation in breast cancer.

Authors:  Edward P Chen; Emer M Smyth
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-08-31       Impact factor: 3.072

2.  An important role of prostanoid receptor EP2 in host resistance to Mycobacterium tuberculosis infection in mice.

Authors:  Vandana Kaul; Debapriya Bhattacharya; Yogesh Singh; Luc Van Kaer; Marc Peters-Golden; William R Bishai; Gobardhan Das
Journal:  J Infect Dis       Date:  2012-10-02       Impact factor: 5.226

3.  Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction.

Authors:  Joshua M Diamond; Tatiana Akimova; Altaf Kazi; Rupal J Shah; Edward Cantu; Rui Feng; Matthew H Levine; Steven M Kawut; Nuala J Meyer; James C Lee; Wayne W Hancock; Richard Aplenc; Lorraine B Ware; Scott M Palmer; Sangeeta Bhorade; Vibha N Lama; Ann Weinacker; Jonathan Orens; Keith Wille; Maria Crespo; David J Lederer; Selim Arcasoy; Ejigayehu Demissie; Jason D Christie
Journal:  Am J Respir Crit Care Med       Date:  2014-03-01       Impact factor: 21.405

4.  PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis.

Authors:  Maozhen Tian; William P Schiemann
Journal:  FASEB J       Date:  2009-11-06       Impact factor: 5.191

5.  Efficient T-cell priming and activation requires signaling through prostaglandin E2 (EP) receptors.

Authors:  Vinatha Sreeramkumar; Miroslav Hons; Carmen Punzón; Jens V Stein; David Sancho; Manuel Fresno; Natalia Cuesta
Journal:  Immunol Cell Biol       Date:  2015-06-08       Impact factor: 5.126

Review 6.  Mast cell function: a new vision of an old cell.

Authors:  Elaine Zayas Marcelino da Silva; Maria Célia Jamur; Constance Oliver
Journal:  J Histochem Cytochem       Date:  2014-07-25       Impact factor: 2.479

Review 7.  Fatty acids, lipid mediators, and T-cell function.

Authors:  Anja J de Jong; Margreet Kloppenburg; René E M Toes; Andreea Ioan-Facsinay
Journal:  Front Immunol       Date:  2014-10-13       Impact factor: 7.561

8.  Prostaglandin E2 reverses curcumin-induced inhibition of survival signal pathways in human colorectal carcinoma (HCT-15) cell lines.

Authors:  Adeeb Shehzad; Salman Ul Islam; Jaetae Lee; Young Sup Lee
Journal:  Mol Cells       Date:  2014-11-26       Impact factor: 5.034

9.  Proinflammatory and immunoregulatory roles of eicosanoids in T cells.

Authors:  Anna Mari Lone; Kjetil Taskén
Journal:  Front Immunol       Date:  2013-06-04       Impact factor: 7.561

Review 10.  The role of mast cells in oral squamous cell carcinoma.

Authors:  Swetha Gudiseva; Arvind Babu Rajendra Santosh; Raviteja Chitturi; Vamsikrishna Anumula; Chandrashekar Poosarla; Venkat Ramana Reddy Baddam
Journal:  Contemp Oncol (Pozn)       Date:  2017-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.